Skip to content
StackItSmart
AHuman RCT or meta-analysis

Fish Oil

Omega-3 · EPA/DHA

Fish oil is a dietary supplement supplying the long-chain marine omega-3 fatty acids EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid). In the bodybuilding/enhancement context it is used as an ancillary "organ-support" agent for its triglyceride-lowering and anti-inflammatory effects. It is one of the better-studied supplements here, with multiple large human RCTs and meta-analyses. Key evidence: at high (roughly 4 g/day prescription-grade) doses it lowers triglycerides by ~30%, and a purified EPA formulation (icosapent ethyl) reduced major cardiovascular events in a high-risk statin-treated population (REDUCE-IT). However, benefit is not universal — a comparably large EPA+DHA trial (STRENGTH) and a general-population trial (VITAL) showed no cardiovascular benefit. The most consistent, replicated harm is a dose-dependent increase in atrial fibrillation (an irregular, potentially serious heart rhythm), clearest above ~1 g/day. There is also a theoretical antiplatelet/bleeding effect, though large surgical and prevention trials did not find increased major bleeding at supplement doses. Fish oil is generally low-risk, is not hepatotoxic, and has no known hormonal/HPTA activity; the main real-world downsides are GI upset and the AF signal. This is educational information, not medical advice.

Clinical readoutAncillary · organ-support
Hepatic strainLow
CardiovascularHigh
HPTA suppressionNone
Half-life
36 h
Route
Oral
Evidence
A
Active
Lipid-lowering and memb…
36 h3 d4.5 d6 d7.5 d
Illustrative single-compartment washout · each mark = one half-life · t½ ≈ Variable and compartment-dependent. Free/plasma EPA and DHA turn over on the order of ~1-2 days, but the physiologically relevant measure is incorporation into membrane and erythrocyte phospholipids, which accumulates and washes out over weeks to months (the erythrocyte 'omega-3 index' reflects intake over roughly the preceding ~3-4 months).
Pharmacology

Mechanism of action

EPA and DHA are polyunsaturated fatty acids that incorporate into cell-membrane phospholipids, partially displacing arachidonic acid. This shifts eicosanoid production toward less inflammatory mediators and generates specialized pro-resolving lipid mediators (resolvins, protectins). Metabolically, they reduce hepatic VLDL/triglyceride synthesis and secretion and increase triglyceride clearance, producing substantial reductions in serum triglycerides. They also alter membrane fluidity and ion-channel/electrophysiologic properties, which is the proposed basis for both antiarrhythmic effects at low intake and the pro-arrhythmic atrial fibrillation signal at higher supplemental doses. Antiplatelet effects arise from reduced thromboxane A2 production.
Kinetics

Pharmacokinetics

Half-life

Variable and compartment-dependent. Free/plasma EPA and DHA turn over on the order of ~1-2 days, but the physiologically relevant measure is incorporation into membrane and erythrocyte phospholipids, which accumulates and washes out over weeks to months (the erythrocyte 'omega-3 index' reflects intake over roughly the preceding ~3-4 months).

Active duration

Lipid-lowering and membrane effects persist as long as tissue enrichment is maintained; steady-state tissue levels take weeks of consistent daily dosing and decline gradually after stopping.

Route

Oral (softgel capsules, liquid, or prescription ethyl-ester/carboxylic-acid formulations).

Metabolism & clearance

Absorbed as fatty acids/monoacylglycerols, incorporated into chylomicrons and membrane phospholipids, and metabolized largely by mitochondrial/peroxisomal beta-oxidation for energy or converted enzymatically (cyclooxygenase, lipoxygenase, cytochrome P450 pathways) into eicosanoids and pro-resolving mediators. Not dependent on a single hepatic enzyme for clearance. Note: PK is presented for washout/monitoring and clinician discussion only, not for any test-timing purpose.

For monitoring and washout planning, not drug-test evasion.

Reported effects

Physiological & performance effects

  • Lowers serum triglycerides by approximately 30% at high (~4 g/day) doses; larger reductions when baseline triglycerides are very high
  • Modestly lowers non-HDL cholesterol and apolipoprotein B at high doses
  • A purified high-dose EPA formulation (icosapent ethyl 4 g/day) reduced major adverse cardiovascular events in high-risk, statin-treated patients with elevated triglycerides (REDUCE-IT)
  • High-dose icosapent ethyl was associated with regression of low-attenuation coronary plaque on CT imaging (EVAPORATE)
  • Anti-inflammatory / pro-resolution effects via membrane incorporation and altered eicosanoid signaling
  • Cardiovascular benefit is not consistent across formulations: an EPA+DHA carboxylic-acid trial (STRENGTH) and a 1 g/day general-population trial (VITAL) showed no reduction in major cardiovascular events
Safety

Adverse effects by system

Cardiovascular

The most consistent adverse effect is a dose-dependent increase in atrial fibrillation. Meta-analyses of cardiovascular outcome RCTs found roughly a 25% relative increase in incident AF (HR ~1.25), greater in trials using >1 g/day (HR ~1.49) than ≤1 g/day (HR ~1.12). In REDUCE-IT, hospitalization for AF/flutter was higher with icosapent ethyl (3.1% vs 2.1%). Otherwise cardiovascular effects on ischemic events range from neutral (STRENGTH, VITAL) to beneficial (REDUCE-IT).

Hepatic

No signal of hepatotoxicity in large human RCTs; fish oil is not associated with liver injury and has been studied (not established) for hepatic steatosis. No routine hepatic warning identified.

Endocrine / HPTA

Not a hormonal agent. No known effect on the hypothalamic-pituitary-testicular axis, testosterone, or gonadotropins; no adequate human data suggesting endocrine suppression.

Reproductive

No known adverse reproductive effects; marine omega-3/DHA is generally considered acceptable in pregnancy for fetal development. No adequate data indicating reproductive harm in the enhancement context.

Neuropsychiatric

No adverse psychiatric signal in large trials; omega-3s have been studied (with mixed results) as an adjunct for mood disorders. No established psychiatric harm.

Renal

No established adverse renal effects in randomized cardiovascular outcome trials. No adequate evidence of nephrotoxicity.

Hematologic

Theoretical antiplatelet/bleeding effect. An EPA-monotherapy meta-analysis found increased total (mostly minor) bleeding (RR ~1.49), and REDUCE-IT showed a non-significant trend toward serious bleeding (2.7% vs 2.1%, P=0.06). However, a dedicated perioperative RCT found no increase in major bleeding (and fewer transfusions), and the VITAL prevention trial found no excess serious bleeding at 1 g/day.

Dermatologic

No significant dermatologic adverse effects established; rash is not a recognized common effect. Occasional reports are anecdotal, not from primary trial data.

Recovery

HPTA suppression & recovery

Suppression: None known

Fish oil is not a hormonal or androgenic agent and has no documented suppressive effect on the hypothalamic-pituitary-testicular axis, so no SERM-based recovery is applicable to it. Any concerns about HPTA function relate to other agents in a regimen, not fish oil, and should be directed to an endocrinologist. Single-SERM approaches only would ever be relevant to hormonal agents; dual-SERM protocols are out of scope.

Bloodwork & vitals

Monitoring

Recommended labs & checks
Fasting lipid panel including triglycerides, LDL-C, non-HDL-C (LDL-C can rise with high-dose EPA+DHA formulations)Baseline and periodic assessment of heart rhythm / symptom review for atrial fibrillationCoagulation status if combined with anticoagulant or antiplatelet therapy or before surgeryErythrocyte omega-3 index where available (reflects tissue exposure)

Cadence: Recheck lipids ~6-12 weeks after starting or changing dose, then periodically; seek prompt evaluation for any new arrhythmia symptoms at any time.

Warning signs — seek care
  • Palpitations, irregular or racing heartbeat, lightheadedness, or shortness of breath (possible atrial fibrillation) — seek medical evaluation
  • Unusual or prolonged bleeding, easy bruising, blood in stool/urine
  • Rising LDL cholesterol on follow-up labs
  • Signs of an allergic reaction (rash, swelling, difficulty breathing)
Do not use if

Contraindications

  • Known allergy to fish or seafood
  • Active clinically significant bleeding or a bleeding disorder, or use with anticoagulants/antiplatelets without physician oversight (theoretical additive bleeding risk)
  • History of, or elevated risk for, atrial fibrillation — discuss with a clinician before higher-dose use given the dose-dependent AF signal
  • Planned surgery/invasive procedures — inform the surgical team (though a large RCT did not find increased major bleeding, individual management should be clinician-directed)
  • Very high triglycerides being treated with an EPA+DHA product, where LDL-C may rise — requires clinician monitoring
Combinations

Interaction profile

  • ContraindicatedWith DNP: Additive cardiovascular strain

Check a specific combination in the interaction checker.

Harm reduction

Reducing harm & when to stop

  • Fish oil is comparatively low-risk, but the atrial fibrillation signal is real and dose-dependent — higher doses (>1 g/day) carry greater AF risk. Discuss higher-dose use with a clinician, especially if you have palpitations, prior AF, or heart disease.
  • If you develop palpitations, an irregular/racing heartbeat, dizziness, or breathlessness, stop and seek medical evaluation for possible atrial fibrillation.
  • If you take anticoagulants or antiplatelet drugs, or have a bleeding disorder, use only under physician supervision and report unusual bleeding or bruising.
  • Inform your surgical/dental team that you take fish oil before any procedure; do not self-manage stopping/continuing — follow clinician guidance.
  • Get a baseline and follow-up lipid panel: high-dose EPA+DHA products can raise LDL cholesterol even while lowering triglycerides.
  • Do not assume fish oil replaces prescribed cardiovascular therapy; cardiovascular benefit was seen only for a specific purified EPA product in a specific high-risk population, and other trials showed no benefit.
  • GI upset (fishy burps, nausea, loose stools) is the most common nuisance effect; taking with food or refrigerating capsules may help — if intolerable, stop.
  • Educational information only, not medical advice, and not a doctor-patient relationship. Consult a qualified physician and obtain regular bloodwork. 21+ only.
Evidence

Citations (8)

Every clinical claim above is tied to a primary source. Overall evidence grade A — graded to the best available evidence for its core claims.

  1. 01

    High-dose (~4 g/day) omega-3 EPA+DHA lowers triglycerides by ≥30%, and EPA+DHA formulations increase LDL-C in patients with very high triglycerides whereas EPA-only does not.

    GuidelinePMID 31422671 ↗

  2. 02

    Icosapent ethyl (purified EPA) 4 g/day reduced major adverse cardiovascular events (~25% relative reduction) in high-risk statin-treated patients with elevated triglycerides; AF/flutter hospitalization was higher (3.1% vs 2.1%) and serious bleeding trended higher (2.7% vs 2.1%, P=0.06).

    RCTPMID 30415628 ↗

  3. 03

    A carboxylic-acid EPA+DHA formulation at 4 g/day showed no reduction in major adverse cardiovascular events versus corn oil, with more gastrointestinal adverse events (24.7% vs 14.7%).

    RCTPMID 33190147 ↗

  4. 04

    Marine n-3 fatty acids at 1 g/day did not reduce major cardiovascular events or cancer in a general population and showed no excess bleeding or serious adverse events.

    RCTPMID 30415637 ↗

  5. 05

    Omega-3 supplementation is associated with a dose-dependent increased risk of atrial fibrillation (overall HR ~1.25; HR ~1.49 for >1 g/day vs ~1.12 for ≤1 g/day).

    Meta-analysisPMID 34612056 ↗

  6. 06

    Meta-analysis of 38 RCTs (149,051 participants) found omega-3 reduced cardiovascular mortality and non-fatal MI, increased incident AF (RR 1.26), and EPA monotherapy increased total bleeding (RR 1.49) and AF (RR 1.35).

    Meta-analysisPMID 34505026 ↗

  7. 07

    Fish oil supplementation (EPA+DHA) did not increase major perioperative bleeding in cardiac surgery patients and was associated with fewer blood transfusions.

    RCTPMID 30571332 ↗

  8. 08

    High-dose icosapent ethyl (4 g/day) was associated with regression of low-attenuation coronary plaque on serial CT angiography.

    RCTPMID 32860032 ↗

Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice